<DOC>
	<DOCNO>NCT02365493</DOCNO>
	<brief_summary>The aim clinical trial determine whether novel combination antibiotic treatment ( vancomycin/daptomycin + beta-lactam ) superior standard antibiotic treatment ( vancomycin/daptomycin ) hospitalise adult Methicillin Resistant Staphylococcus aureus bacteraemia . The hypothesis addition beta-lactam antibiotic ( antibitoics penicillin family ) standard therapy lead efficient bacterial kill hence lead faster clearance bacteria blood stream area infection , thereby reduce risk spread infection death . The study design investigator-initiated , multi-centre , open-label , randomise control trial . This include 440 participant diagnose Methicillin Resistant Staphylococcus aureus bacteraemia recruit period 4 year ( July 2015 - June 2019 ) within Infectious Diseases inpatient unit across 21 hospital site include 18 within Australia 3 locate Singapore . Participation voluntary subject inform consent . The participant randomise 1:1 either standard therapy group combination therapy group . The combination therapy include treatment intravenous beta-lactam first 7 day treatment , addition standard treatment ( either vancomycin daptomycin ) . The primary outcome measure complication-free survival 90 day post randomisation .</brief_summary>
	<brief_title>Combination Antibiotic Therapy Methicillin Resistant Staphylococcus Aureus Infection</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Cefazolin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<mesh_term>Cloxacillin</mesh_term>
	<criteria>1 . Age &gt; = 18 year . 2 . ≥1 set blood culture positive MRSA 3 . Able randomize within 72 hour blood culture collect . 4 . Likely remain inpatient 7 day follow randomization 1 . Previous type 1 hypersensitivity reaction ßlactams 2 . Polymicrobial bacteraemia ( count contaminant ) 3 . Previous participation trial 4 . Known pregnancy 5 . Current βlactam antibiotic therapy cease substituted 6 . Participant 's primary clinician unwilling enrol patient 7 . Moribund ( expect die next 48 hour without treatment ) 8 . Treatment limitation preclude use antibiotic Note NOT plan exclude participant renal failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Methicillin-Resistant Staphylococcus aureus ( MRSA )</keyword>
</DOC>